光蛋白聚糖在钙化性主动脉瓣疾病中的作用机制与潜在治疗靶点的研究进展  

The Mechanisms of Lumican in Calcific Aortic Valve Disease and Its Potential Therapeutic Targets

作　　者：段青松 胡厚祥[1] DUAN Qingsong;HU Houxiang(Department of Cardiology,Affiliated Hospital of North Sichuan Medical College,Nanchong 637000,Sichuan,China;Department of Cardiology,Guangyuan First People’s Hospital,Guangyuan 628000,Sichuan,China)

机构地区：[1]川北医学院附属医院心内科,四川南充637000 [2]广元市第一人民医院心内科,四川广元628000

出　　处：《心血管病学进展》2025年第4期346-350,共5页Advances in Cardiovascular Diseases

基　　金：四川省卫生健康委员会医学科技项目(21ZD004)。

摘　　要：钙化性主动脉瓣疾病(CAVD)是导致主动脉瓣狭窄的主要原因。CAVD的进展与炎症反应、细胞外基质重塑和钙化等生物学过程密切相关。富含亮氨酸的小蛋白多糖家族成员——重组人光蛋白聚糖在CAVD中的作用近期备受关注。现综述光蛋白聚糖的表达、作用机制及其在CAVD中的促进作用,并探讨其作为潜在治疗靶点的可行性。Calcific aortic valve disease(CAVD)is a leading cause of aortic valve stenosis.The progression of CAVD is closely associated with biological processes such as inflammation,extracellular matrix remodeling,and calcification.Recently,the role of lumican,a member of the small leucine-rich proteoglycan family,has garnered significant attention in CAVD.This review summarizes the expression and mechanisms of lumican in CAVD and discusses its potential as a therapeutic target.

关 键 词：钙化性主动脉瓣疾病 光蛋白聚糖 细胞外基质重塑 

分 类 号：R654.2[医药卫生—外科学]